- Cell Biology
- Product Type
- Research Area
- New Products
- About Tocris
- Contact Us
Ketamine is a water soluble phencyclidine derivative with an asymmetric carbon atom; it has two enantiomers. Ketamine is metabolized in the liver via N-demethylation and ring hydroxylation pathways and the main metabolites are norketamine and its hydroxylated derivatives.
|Cat No||Product Name / Activity|
|Enhances AMPA currents; decreases D-serine (a NMDA co-agonist); lacks ketamine-related side effects|
|Decreases D-serine (a NMDA co-agonist); antidepressant|
|Enhances AMPA currents: antidepressant|
|Non-competitive NMDA receptor antagonist|
|NMDA receptor antagonist; enantiomer of ketamine hydrochloride (Cat. No. 3131); neuroprotective|
|Potent non-competitive NMDA antagonist; antinociceptive|
|NMDA receptor modulator; analgesic|
|NMDA receptor modulator; analgesic|
Ketamine is a water soluble phencyclidine derivative with an asymmetric carbon atom; it has two enantiomers. It is lipid soluble and undergoes rapid breakdown and redistribution to peripheral tissues. Ketamine is a noncompetitive antagonist of the NMDA receptor (NMDAR), but it also interacts with opioid receptors, cholinergic (nAChR and mAChR), purinergic (P2X, P2Y and adenosine receptors), monoamine and adrenoceptor systems. Ketamine stimulates the sympathetic nervous system, which in turn stimulates the cardiovascular system, leading to increased blood pressure and elevated heart rate.
Ketamine is metabolized in the liver via N-demethylation and ring hydroxylation pathways, the main metabolites being norketamine, hydroxyketamine, dehydronorketamine and hydroxynorketamine (HNK). HNKs enantioselectively decrease levels of an NMDA co-agonist D-serine. D-serine is associated with NMDA receptor-mediated neurotoxicity and neurodegeneration.
Ketamine appears to be an attractive antidepressant treatment, because its action has rapid onset and is long-lasting. However, it also has a number of undesired side effects, including disruption of long-term potentiation (LTP) and thus memory formation. Until recently the antidepressant effects of ketamine were thought to be mediated through the NMDAR, however studies blocking ketamine binding at NMDAR did not inhibit its antidepressant effect. Research showing that lower concentrations of ketamine were needed to reduce depression-like symptoms in female mice compared male mice, led to the discovery of high concentrations of the HNK metabolite in the brains of female mice. The 2R,6R-enantiomer of HNK had a potent antidepressive effect in mice and was shown not to bind to or inhibit the NMDAR. The 2R,6R-HNK enantiomer also lacked the side effects of ketamine.
The AMPA receptor (AMPAR) has become a main prospective target for the antidepressant action of ketamine and its metabolites, because blocking the AMPAR reduced and even reversed the antidepressant effects of HNK in mice. HNKs have also been shown to enhance AMPAR currents. However, to date there has been no conclusive evidence showing that the antidepressant effects of HNKs are mediated through AMPAR activation.
Ketamine was first made commercially available in the 1970s as a general anesthetic. Ketamine has subsequently been shown to have a wide range of actions, including antidepressant, neuroprotective and anti-inflammatory effects. Due to the role of NMDA receptors in pain, Ketamine is also being investigated for its antinociceptive effects, in particular for the treatment of neuropathic pain.
Tocris offers the following scientific literature for Ketamine and Metabolites to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.